Can a Medicare Advantage insurer be great at drug development for their target audience?
The top team at Clover Health believes they can do something no other health insurer in the US has attempted: Build new drugs from scratch.
The buzzy company run by Vivek Garipalli — who’s raised hundreds of millions of dollars for his new-wave insurance company — tapped ex-Pfizer exec Cheng Zhang to run his new biotech startup, Clover Therapeutics. And now Zhang and CSO Marcel van der Brug have allied with none other than Genentech to start putting their extensive healthcare data to work with genetics experts to start hunting new drugs that afflict their population of aging customers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.